Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1896279 | 0.96 | TLR7 (0.39) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL1896802 | 0.94 | TLR8 (0.38) | TLR7TLR8ALDH1A1SMN1; SMN2 | |
| SCHEMBL1894486 | 0.90 | TLR7 (0.40) | TLR7TLR8ALDH1A1SMN1; SMN2 | |
| SCHEMBL1896081 | 0.85 | TLR7 (0.47) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL1900262 | 0.84 | TLR8 (0.34) | TLR7TLR8 | |
| SCHEMBL1896335 | 0.83 | TLR7 (0.47) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL5259308 | 0.82 | GAA (0.40) | TLR7TLR8CNR1CNR2SMN1; SMN2 | |
| SCHEMBL3971953 | 0.81 | TLR7 (0.47) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL4333747 | 0.80 | TLR7 (0.46) | TLR7TLR8CNR2 | |
| SCHEMBL1960054 | 0.80 | TLR7 (0.42) | TLR7TLR8PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939526-B2 | Sulfone substituted imidazo ring ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-05-10 | — | — | US | disclosed |
| US-20070155767-A1 | Sulfone substituted imidazo ring ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-05 | — | — | US | disclosed |
| EP-1694674-A2 | SULFONE SUBSTITUTED IMIDAZO RING ETHERS | 3M Innovative Properties Company (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005076783-A2 | SULFONE SUBSTITUTED IMIDAZO RING ETHERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155767-A1 | Sulfone substituted imidazo ring ethers | IL2, IL4, IFNG | TLR7 82/4885TLR8 145/4885PDE4A 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.